JP2023502968A5 - - Google Patents

Info

Publication number
JP2023502968A5
JP2023502968A5 JP2022528305A JP2022528305A JP2023502968A5 JP 2023502968 A5 JP2023502968 A5 JP 2023502968A5 JP 2022528305 A JP2022528305 A JP 2022528305A JP 2022528305 A JP2022528305 A JP 2022528305A JP 2023502968 A5 JP2023502968 A5 JP 2023502968A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence described
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022528305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502968A (ja
JP7722990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/060596 external-priority patent/WO2021097360A1/en
Publication of JP2023502968A publication Critical patent/JP2023502968A/ja
Publication of JP2023502968A5 publication Critical patent/JP2023502968A5/ja
Priority to JP2025104401A priority Critical patent/JP7894099B2/ja
Application granted granted Critical
Publication of JP7722990B2 publication Critical patent/JP7722990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528305A 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン Active JP7722990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104401A JP7894099B2 (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962936002P 2019-11-15 2019-11-15
US62/936,002 2019-11-15
US202063074912P 2020-09-04 2020-09-04
US63/074,912 2020-09-04
PCT/US2020/060596 WO2021097360A1 (en) 2019-11-15 2020-11-13 Modified immunoglobulins for targeting amyloid deposits

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104401A Division JP7894099B2 (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Publications (3)

Publication Number Publication Date
JP2023502968A JP2023502968A (ja) 2023-01-26
JP2023502968A5 true JP2023502968A5 (cg-RX-API-DMAC7.html) 2023-11-20
JP7722990B2 JP7722990B2 (ja) 2025-08-13

Family

ID=75912899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528305A Active JP7722990B2 (ja) 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン
JP2025104401A Active JP7894099B2 (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104401A Active JP7894099B2 (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Country Status (11)

Country Link
US (5) US20220411489A1 (cg-RX-API-DMAC7.html)
EP (1) EP4058479A4 (cg-RX-API-DMAC7.html)
JP (2) JP7722990B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113950A (cg-RX-API-DMAC7.html)
CN (1) CN115298214A (cg-RX-API-DMAC7.html)
AU (1) AU2020385183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009273A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158206A1 (cg-RX-API-DMAC7.html)
IL (1) IL292903B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005850A (cg-RX-API-DMAC7.html)
WO (1) WO2021097360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097360A1 (en) 2019-11-15 2021-05-20 University Of Tennessee Research Foundation Modified immunoglobulins for targeting amyloid deposits
US20240003912A1 (en) * 2020-12-04 2024-01-04 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
US20240216556A1 (en) * 2021-05-05 2024-07-04 University Of Tennessee Research Foundation Peptide-fc fusions for treating amyloid disorders
WO2022246433A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
WO2023043658A2 (en) * 2021-09-14 2023-03-23 Caelum Biosciences Method of treating multiple myeloma
WO2023086989A1 (en) * 2021-11-12 2023-05-19 Adrx, Inc. Transthyretin (ttr) monomer binding antibodies
WO2023220234A1 (en) * 2022-05-11 2023-11-16 Alexion Pharmaceuticals, Inc. High sensitivity biotinylated peptide binding elisa assay
US20260070962A1 (en) * 2022-09-02 2026-03-12 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
KR20260066110A (ko) 2023-09-07 2026-05-12 유니버시티 오브 테네시 리서치 파운데이션 아밀로이드 질환을 진단하는 방법
WO2025212955A1 (en) 2024-04-05 2025-10-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2026055521A1 (en) * 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH09506262A (ja) * 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ES2345746T3 (es) * 1998-05-21 2010-09-30 University Of Tennessee Research Foundation Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
CN101415724B (zh) 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
ATE439443T1 (de) 2005-06-17 2009-08-15 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2009086539A2 (en) * 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
JP7449092B2 (ja) 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用
KR102607629B1 (ko) 2017-06-29 2023-12-01 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 아밀로이드 침착 질환의 치료를 위한 키메라 항체
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
WO2021097360A1 (en) 2019-11-15 2021-05-20 University Of Tennessee Research Foundation Modified immunoglobulins for targeting amyloid deposits
WO2022246433A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Similar Documents

Publication Publication Date Title
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのc5抗体及び方法
JP2025134876A5 (cg-RX-API-DMAC7.html)
CA2762594C (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
US12264195B2 (en) Modified immunoglobulins for targeting amyloid deposits
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2012515746A (ja) 抗cd160モノクローナル抗体及びその使用
NZ717476A (en) Anti-garp protein and uses thereof
TW200840821A (en) Methods of purifying anti A beta antibodies
JP2005528914A5 (cg-RX-API-DMAC7.html)
AU2022273136A1 (en) Binding molecule against dll3 and use thereof
IL297143A (en) Anti-cd98 antibodies and their uses
JP7618240B2 (ja) 脳神経系疾患の予防または治療用組成物
CN115109156A (zh) 一种靶向bcma的纳米抗体及其应用
US20190330318A1 (en) Anti-hspa5 (grp78) antibodies and uses thereof
TW201134489A (en) Basigin binding proteins
IL323457A (en) CD19/CD38 multispecific antibodies
JP2022521305A (ja) 抗pd-l1抗体及びその使用
EP3966239A1 (en) Anti-sema3a antibodies and their uses for treating eye or ocular diseases
JP2023533533A5 (cg-RX-API-DMAC7.html)
WO2022051223A1 (en) Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
US20240376222A1 (en) Tfr antigen binding proteins and uses thereof
JP2024535851A5 (cg-RX-API-DMAC7.html)
JP2023536630A5 (cg-RX-API-DMAC7.html)